VIGL — Vigil Neuroscience Income Statement
0.000.00%
Last trade - 00:00
- $101.85m
- -$16.09m
- 23
- 35
- 17
- 14
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 27.2 | 42.4 | 68.9 | 88.9 |
Operating Profit | -27.2 | -42.4 | -68.9 | -88.9 |
Total Net Non Operating Interest Income / Expense | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -28.5 | -43.3 | -68.3 | -82.6 |
Net Income After Taxes | -28.5 | -43.3 | -68.3 | -82.6 |
Net Income Before Extraordinary Items | ||||
Net Income | -28.5 | -43.3 | -68.3 | -82.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -28.5 | -43.3 | -68.3 | -82.6 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -1.01 | -1.53 | -2.16 | -2.13 |
Dividends per Share |